ArticleOncoimmunology2013
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 76 citations in OpenAlex.
- Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.Signal transduction and targeted therapy · 2024Review
- Article
- TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of CancerTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Review
- Article
- Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?International journal of molecular sciences · 2021Review
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Immunotherapies for bladder cancer: a new hope.Current opinion in urology · 2015Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Oncoimmunology · 2015Article
- New cell sources for T cell engineering and adoptive immunotherapy.Cell stem cell · 2015Review
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.Oncoimmunology · 2015Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology · 2014Review
- Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology · 2014Review
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.Oncoimmunology · 2014Article
- Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.Oncoimmunology · 2014Article
- Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.Immunological reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell transfer (ACT) represents a prominent form of immunotherapy against malignant diseases. ACT is conceptually distinct from dendritic cell-based approaches (which de facto constitute cellular vaccines) and allogeneic transplantation (which can be employed for the therapy of hematopoietic tumors) as it involves the isolation of autologous lymphocytes exhibiting antitumor activity, their expansion/activation ex vivo and their reintroduction into the patient. Re-infusion is most often performed in the context of lymphodepleting regimens (to minimize immunosuppression by host cells) and combined with immunostimulatory interventions, such as the administration of Toll-like receptor agonists. Autologous cells that are suitable for ACT protocols can be isolated from tumor-infiltrating lymphocytes or generated by engineering their circulating counterparts for the expression of transgenic tumor-specific T-cell receptors. Importantly, lymphocytes can be genetically modified prior to re-infusion for increasing their persistence in vivo, boosting antitumor responses and minimizing side effects. Moreover, recent data indicate that exhausted antitumor T lymphocytes may be rejuvenated in vitro by exposing them to specific cytokine cocktails, a strategy that might considerably improve the clinical success of ACT. Following up the Trial Watch that we published on this topic in the third issue of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.